Visfatin is regulated by rosiglitazone in type 2 diabetes mellitus and influenced by NFκB and JNK in human abdominal subcutaneous adipocytes

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  McGee, Kirsty C ^a   Harte, Alison L ^a   da Silva, Nancy F ^a   Al Daghri, Nasser ^b   Creely, Steven J ^a   Kusminski, Christine M ^a   Tripathi, Gyanendra ^a   Levick, Paul L ^c   Khanolkar, Manish ^d   Evans, Marc ^d   Chittari, Madhu V ^a   Patel, Vinod ^e   Kumar, Sudhesh ^a   McTernan, Philip G ^a  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c Priory Hospital   (United Kingdom)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e GEORGE ELIOT HOSPITAL NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RECOMBINANT INTERLEUKIN 6; RESISTIN; ROSIGLITAZONE; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE 1; TUMOR NECROSIS FACTOR ALPHA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CYTOKINE; I KAPPA B KINASE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN; RECOMBINANT PROTEIN;

ABDOMINAL SUBCUTANEOUS FAT; ADIPOCYTE; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; ENZYME BLOOD LEVEL; ENZYME INHIBITION; ENZYME REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; UPREGULATION; BLOOD; CASE CONTROL STUDY; CELL SEPARATION; CULTURE MEDIUM; CYTOLOGY; DRUG ANTAGONISM; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; OBESITY; PHOSPHORYLATION; SECRETION;

ADIPOCYTES; ADIPOKINES; ADIPOSITY; ADULT; CASE-CONTROL STUDIES; CELL SEPARATION; CULTURE MEDIA, CONDITIONED; CYTOKINES; DIABETES MELLITUS, TYPE 2; FEMALE; GENE EXPRESSION REGULATION; HUMANS; I-KAPPA B KINASE; IMMUNOHISTOCHEMISTRY; INSULIN; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; NF-KAPPA B; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PHOSPHORYLATION; RECOMBINANT PROTEINS; SUBCUTANEOUS FAT, ABDOMINAL; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79958255699     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020287     Document Type: Article

References (46)

1. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, et al. (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307: 426-430.
2. Jia SH, Li Y, Parodo J, Kapus A, Fan L, et al. (2004) Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 113: 1318-1327.
3. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, et al. (2006) Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 91: 295-299.
4. Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, et al. (2007) Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 76: 24-29.
5. Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, et al. (2006) The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 49: 1909-1914.
6. Zhu J, Schott M, Liu R, Liu C, Shen B, et al. (2008) Intensive Glycemic Control Lowers Plasma Visfatin Levels in Patients with Type 2 Diabetes. Horm Metab Res.
7. Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, et al. (2005) Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 54: 2911-2916.
8. Oki K, Yamane K, Kamei N, Nojima H, Kohno N, (2007) Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin Endocrinol (Oxf) 67: 796-800.
9. Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, et al. (2006) Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 91: 3165-3170.
10. Seo JA, Jang ES, Kim BG, Ryu OH, Kim HY, et al. (2007) Plasma visfatin levels are positively associated with circulating interleukin-6 in apparently healthy Korean women.
11. Smith J, Al-Amri M, Sniderman A, Cianflone K, (2006) Visfatin concentration in Asian Indians is correlated with high density lipoprotein cholesterol and apolipoprotein A1. Clin Endocrinol (Oxf) 65: 667-672.
12. Haider DG, Mittermayer F, Schaller G, Artwohl M, Baumgartner-Parzer, et al. (2006) Free fatty acids normalize a rosiglitazone-induced visfatin release. Am J Physiol Endocrinol Metab 291: E885-890.
13. Pfützner A, Hanefeld M, Lübben G, Weber M, Karagiannis E, et al. (2007) Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk - results from the PIOSTAT study. Horm Metab Res 39: 764-768.
14. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T, (2007) Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 56: 451-458.
15. Choi KC, Ryu OH, Lee KW, Kim HY, Seo JA, et al. (2005) Effect of PPAR-alpha and-gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats. Biochem Biophys Res Commun 336: 747-753.
16. Varma V, Yao-Borengasser A, Rasouli N, Bodles AM, Phanavanh B, et al. (2007) Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. J Clin Endocrinol Metab 92: 666-672.
17. Hammarstedt A, Pihlajamaki J, Rotter Sopasakis V, Gogg S, Jansson PA, et al. (2006) Visfatin is an adipokine, but it is not regulated by thiazolidinediones. J Clin Endocrinol Metab 91: 1181-1184.
18. Kloting N, Kloting I, (2005) Visfatin: gene expression in isolated adipocytes and sequence analysis in obese WOKW rats compared with lean control rats. Biochem Biophys Res Commun 332: 1070-1072.
19. Sandeep S, Velmurugan K, Deepa R, Mohan V, (2007) Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism 56: 565-570.
20. Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J, Kocelak P, Semik-Grabarczyk E, et al. (2007) Serum concentration of visfatin in obese women. Metabolism 56: 1131-1134.
21. Chang Y, Chang T, Lee W, Chuang L, (2010) The relationship of visfatin/pre-B-Cell colony-enhancing factor/nicotinamide phosphoribosyltransferase in adipose tissue with inflammation, insulin resistance, and plasma lipids. Metab Clin Exp 59 (1): 93-99.
22. Xie H, Tang SY, Luo XH, Huang J, Cui RR, et al. (2007) Insulin-like effects of visfatin on human osteoblasts. Calcif Tissue Int 80: 201-210.
23. Kendal CE, Bryant-Greenwood GD, (2007) Pre-B-cell colony-enhancing factor (PBEF/Visfatin) gene expression is modulated by NF-kappaB and AP-1 in human amniotic epithelial cells. Placenta 28: 305-314.
24. Kim S, Bae Y, Bae S, Choi K, Yoon K, et al. (2008) Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta 1783: 886-895.
25. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, et al. (2007) Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 178: 1748-1758.
26. Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, et al. (2005) Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes. J Endocrinol 185: R1-8.
27. Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, et al. (2005) Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 289: E586-590.
28. McTernan PG, Anwar A, Eggo MC, Barnett AH, Stewart PM, et al. (2000) Gender differences in the regulation of P450 aromatase expression and activity in human adipose tissue. Int J Obes Relat Metab Disord 24: 875-881.
29. McTernan PG, Harte AL, Anderson LA, Green A, Smith SA, et al. (2002) Insulin and rosiglitazone regulation of lipolysis and lipogenesis in human adipose tissue in vitro. Diabetes 51: 1493-1498.
30. Harte AL, McTernan PG, McTernan CL, Smith SA, Barnett AH, et al. (2003) Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes. Diabetes Obes Metab 5: 302-10.
31. Harte A, McTernan P, Chetty R, Coppack S, Katz J, et al. (2005) Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone. Circulation 111: 1954-1961.
32. McTernan PG, Fisher FM, Valsamakis G, Chetty R, Harte A, et al. (2003) Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab 88: 6098-6106.
33. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
34. Bradford MM, (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
35. Samal B, Sun Y, Stearns G, Xie C, Suggs S, et al. (1994) Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 14 (2): 1431-1437.
36. Revollo JR, Korner A, Mills KF, Satoh A, Wang T, et al. (2007) Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 6 (5): 363-375.
37. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, et al. (2001) Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 50: 2199-2202.
38. Filippatos TD, Derdemezis CS, Kiortsis DN, Tselepis AD, Elisaf MS, (2007) Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest 30: 323-326.
39. Garten A, Petzold S, Barnikol-Oettler A, Körner A, Thasler WE, et al. (2010) Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. Biochem Biophys Res Commun 392 (1): 376-81.
40. Skop V, Kontrová K, Zídek V, Sajdok J, Pravenec M, et al. (2009) Autocrine effects of visfatin on hepatocyte sensitivity to insulin action. Physiol Res.
41. Ognjanovic S, Bao S, Yamamoto SY, Garibay-Tupas J, Samal B, et al. (2001) Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J Mol Endocrinol 26: 107-117.
42. Chen WP, Bao JP, Feng J, Hu PF, Shi ZL, et al. (2010) Increased serum concentrations of visfatin and its production by different joint tissues in patients with osteoarthritis. Clin Chem Lab Med 48: 1141-5.
43. Aller R, de Luis DA, Izaola O, Sagrado MG, Conde R, et al. (2009) Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease. Dig Dis Sci 54 (8): 1772-7.
44. Liu SW, Qiao SB, Yuan JS, Liu DQ, (2009) Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf) 71 (2): 202-7.
45. Curat CA, Wegner V, Sengenès C, Miranville A, Tonus C, et al. (2006) Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 49 (4): 744-7.
46. Mayi TH, Duhem C, Copin C, Bouhlel MA, Rigamonti E, et al. (2010) Visfatin is induced by peroxisome proliferator-activated receptor gamma in human macrophages. FEBS J 277 (16): 3308-20.